- Home
- UNCY vs IMRX Comparison
UNCY vs IMRX Comparison
Compare UNCY & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- IMRX
- Stock Information
- Founded
- UNCY 2016
- IMRX 2008
- Country
- UNCY United States
- IMRX United States
- Employees
- UNCY N/A
- IMRX N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- IMRX Health Care
- Exchange
- UNCY Nasdaq
- IMRX Nasdaq
- Market Cap
- UNCY 58.7M
- IMRX 62.7M
- IPO Year
- UNCY 2021
- IMRX 2021
- Fundamental
- Price
- UNCY $0.62
- IMRX $1.76
- Analyst Decision
- UNCY Strong Buy
- IMRX Buy
- Analyst Count
- UNCY 4
- IMRX 7
- Target Price
- UNCY $5.50
- IMRX $12.20
- AVG Volume (30 Days)
- UNCY 1.0M
- IMRX 319.9K
- Earning Date
- UNCY 03-27-2025
- IMRX 03-04-2025
- Dividend Yield
- UNCY N/A
- IMRX N/A
- EPS Growth
- UNCY N/A
- IMRX N/A
- EPS
- UNCY N/A
- IMRX N/A
- Revenue
- UNCY N/A
- IMRX N/A
- Revenue This Year
- UNCY N/A
- IMRX N/A
- Revenue Next Year
- UNCY N/A
- IMRX N/A
- P/E Ratio
- UNCY N/A
- IMRX N/A
- Revenue Growth
- UNCY N/A
- IMRX N/A
- 52 Week Low
- UNCY $0.20
- IMRX $1.00
- 52 Week High
- UNCY $1.80
- IMRX $7.68
- Technical
- Relative Strength Index (RSI)
- UNCY 51.79
- IMRX 40.02
- Support Level
- UNCY $0.57
- IMRX $1.70
- Resistance Level
- UNCY $0.65
- IMRX $1.92
- Average True Range (ATR)
- UNCY 0.05
- IMRX 0.09
- MACD
- UNCY 0.01
- IMRX -0.01
- Stochastic Oscillator
- UNCY 76.36
- IMRX 15.00
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.